Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Prolactinomas
NCT03400865Unknown
- Start
- Oct 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydroxychloroquine in prolactinoma. Primary endpoint: Change from baseline on prolactin level at 6 months. Status: unknown.
02
Drugs
hydroxychloroquine
03
Conditions
prolactinoma
Beyond the preview
Go deeper on NCT03400865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400865.